التفاصيل البيبلوغرافية
| العنوان: |
Medication Pipeline Schizophrenia and PTSD. |
| المؤلفون: |
Miller, John |
| المصدر: |
Psychiatric Times; Jan2024, Vol. 41 Issue 1, p1-12, 5p |
| مصطلحات موضوعية: |
DRUG therapy for schizophrenia, MENTAL illness drug therapy, DRUG approval, DRUG efficacy, PSYCHIATRY, PARASYMPATHOMIMETIC agents, SODIUM channel blockers, SEROTONIN antagonists, POST-traumatic stress disorder, MUSCARINIC agonists, CELL receptors, MEMBRANE proteins, DRUG development, ANTIPSYCHOTIC agents, ASPARTIC acid, CARRIER proteins, PATIENT safety, PSYCHOTHERAPY, PHARMACODYNAMICS, CHEMICAL inhibitors |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
The article discusses the novel agents and other treatments for psychiatric disorders, particularly schizophrenia and posttraumatic stress disorders (PTSD), that are under clinical trials. Also cited are the new drug application filed by Karuna Therapeutics with the U.S. Food and Drug Administration (FDA) for KarXT as schizophrenia treatment in adults and the other drugs like emraclidine from Cerevel Therapeutics and roluperidone from Minerva Neurosciences, Inc. |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder